Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

868P - A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts)

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Head and Neck Cancers

Presenters

Paolo Bossi

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

P. Bossi1, C. Resteghini1, E. Orlandi2, P. Nicolai3, B. Vischioni2, P. Castelnuovo4, M. Turri-Zanoni4, M. Ferrari5, V. Rampelli5, N. Facchinetti2, S. Gambazza6, G. Calareso7, P. Quattrone8, R. Ingargiola2, A. Cavallo9, M. Franceschini9, A. Tuzi10, L. Mariani11, L.F. Licitra12

Author affiliations

  • 1 Head And Neck Cancer Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20100 - milano/IT
  • 2 Radiation Oncology Clinical Department, National Center of Oncological Hadrontherapy (CNAO), Pavia/IT
  • 3 Section Of Otorhinolaryngology - Head And Neck Surgery, Department Of Neurosciences, University of Padua - "Azienda Ospedaliera di Padova", Padua/IT
  • 4 Department Of Otorhinolaryngology, University of Insubria and ASST Sette Laghi., Varese/IT
  • 5 Unit Of Otorhinolaryngol - Head And Neck Surgeryogy, Department of Medical and Surgical Specialties, Radiologic Sciences, and Public Health, University of Brescia - "ASST Spedali Civili di Brescia", Brescia/IT
  • 6 Laboratory Of Medical Statistics And Biometry, 'giulio A. Maccacaro', Department of Clinical Sciences and Community Health, University of Milan, Milan/IT
  • 7 Radiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 8 Pathology Unit,, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan/IT
  • 9 Radiotherapy 2 Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan/IT
  • 10 Medical Oncology, ASST - Sette Laghi, 21100 - Varese/IT
  • 11 Clinical Epidemiology And Trial Organization Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan/IT
  • 12 Head And Neck Medical Oncology Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 868P

Background

Unresectable advanced sinonasal epithelial tumors are rare diseases having an overall dismal prognosis (5-year reported PFS less than 15%). No standard treatment is recognized. This prospective study explored the safety and activity of a multimodality treatment modulated by histology, molecular profile and response to IC.

Methods

Pts with untreated inoperable squamous cell carcinoma (SCC), p53 wild-type intestinal type adenocarcinoma (ITAC), sinonasal undifferentiated and neuroendocrine carcinoma (SNUC; SNEC) and Hyams grade III olfactory neuroblastoma (ONB) were enrolled in a single-arm, open-label, phase II, multicenter clinical trial between 2013 and 2018. For each pt, a multidisciplinary team evaluated the best curative treatment. Pts were treated with up to 5 IC cycles, whose regimen was selected according to histotype. Photon and/or proton/carbon ion-based RT was employed according to disease site, stage and IC response. Primary endpoint was 5-year PFS, secondary endpoints were overall survival (OS), radiological response as per RECIST 1.1, safety.

Results

Out of 27 enrolled pts, 25 resulted evaluable for primary endpoint. One pts withdrew from the trial and another one was discontinued by the investigator. Five-year PFS was 26.8% (95% CI 12.6 – 57.1), with a median PFS of 18 months. Five-year OS was 23.8% (95% CI, 9.5 – 59.3), with a median OS of 27 months. The overall response rate to IC was 40%, representing a prognostic factor for 5-yr OS (33.3% in pts with response to IC vs 17.9% in pts without response to IC). Overall treatment safety was in line with multimodality intensive head and neck cancer treatments (3% of pts with G3-4 adverse event during IC). At a median follow up of 27 months, 5 G3-4 RT induced late adverse events have been recorded (1 case of G3 neurotoxicity, 2 cases of G3 hearing impairment, 2 cases of G3 xerostomia). No toxic deaths were recorded.

Conclusions

Multimodal combination of IC and innovative RT provide survival rates only slightly greater than previous experiences, underscoring the need for further treatment improvement. Response to IC confirmed its predictive value on survival. The overall treatment safety is acceptable.

Clinical trial identification

NCT02099188.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Supported by Fondazione Regionale per la Ricerca Biomedica.

Disclosure

P. Bossi: Financial Interests, Institutional, Research Grant: GlaxoSmithKline, MSD, Sanofi, Bristol Myers Squibb. C. Resteghini: Financial Interests, Personal, Advisory Board: Sun Pharma. B. Vischioni: Financial Interests, Personal, Invited Speaker: Merck. N. Facchinetti: Financial Interests, Institutional, Sponsor/Funding: Helsinn Healthcare SA. L.F. Licitra: Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene International, Debiopharm International SA, Eisai, Exelixis inc, Hoffmann-La Roche ltd, IRX Therapeutics inc, Medpace inc, Merck–Serono, MSD, Novartis, Pfizer, Roche.; Financial Interests, Personal, Advisory Role: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, MSD, Merck–Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm International SA, Sobi, Ipsen, Incyte Biosciences Italy srl, Doxa Pharma, Amgen, Nanobiotics Sa and GlaxoSmithKline. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.